Clinical trials have increased in number and have become more complex, decentralized, and patient-centric. While this puts pressure on clinical drug supply, it also brings new opportunities.
Insights on Life Sciences
Chinese biopharma is making a mark on the global stage as the rapidly evolving regulatory landscape and maturing innovation ecosystem spur significant value creation.
As cloud technology matures, life-sciences companies are generating new paths to business value beyond the cost efficiencies that cloud migrations typically target.
Amid the COVID-19 crisis, the CEO of the Coalition for Epidemic Preparedness Innovations explains his five-year strategy that includes reducing vaccine timelines.
Digital marketing offers medtech companies powerful ways to personalize engagement with healthcare professionals and respond to their changing needs.
Pharmaceutical supply chains have become global and complex. With more outsourcing, new modalities, and novel ways to reach patients, it’s critical to ensure that they can withstand shocks.
Angela Hwang, Pfizer’s head of biopharmaceuticals, talks about breaking new ground when the pressure is on—and how having a deep company heritage can help.
By rethinking the approach to regulatory submissions, pharma companies can reduce timelines and increase their chances of successful product approvals.
Moderna’s delivery of a COVID-19 vaccine comes on the heels of revolutionary science that may accelerate innovation across the industry well into the future.